Inadequate ovarian function suppression and endocrine therapy manipulations in premenopausal patients with early breast cancer on adjuvant LHRH agonist and aromatase inhibitor: a cohort study

ESMO Open 2026 Open access

Read full text
Authors: C. Valenza, J.D. Etessami, M. Milano, N. Papadopoulos, M. Alvino, G. Antonarelli, N. Bianco, C. Sangalli, D. Trapani, G. Pravettoni, E. Omodeo Salè, R. Passerini
+3 more M. Colleoni, E. Munzone, G. Curigliano
DOI: 10.1016/j.esmoop.2026.106079
Cited by: 2
References: 17

Abstract

BACKGROUND: Up to 20% of premenopausal patients with early breast cancer (eBC) receiving adjuvant endocrine therapy with luteinizing hormone-releasing hormone agonists (LHRHas) plus aromatase inhibitors (AIs) exhibit inadequate ovarian function suppression (iOFS), defined by elevated serum estradiol (E2) levels. In clinical practice, endocrine therapy manipulations (ETMs) are frequently used to manage iOFS, as AIs are ineffective when iOFS occurs. However, the dynamics of serum E2 during LHRHa therapy and their changes after ETMs remain poorly characterized. METHODS: This is a single-center cohort study including premenopausal women with eBC receiving adjuvant LHRHa plus AI who exhibited iOFS (E2 ≥24 ng/l on immune assays) between 2015 and 2024. The primary endpoint was time to optimal OFS (

Fields of Study & Subjects

Hypothalamic control of reproductive hormones Menopause: Health Impacts and Treatments Growth Hormone and Insulin-like Growth Factors

Publication details

Journal / source
ESMO Open
Publisher
Elsevier BV
Volume
11
Issue
2
Pages
106079–106079
Publication date
1 February 2026
Language
EN